New pill shows promise in taming Hard-to-Treat blood cancers

NCT ID NCT02029443

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About 306 adults took part, and the drug works by blocking a protein that helps cancer cells grow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia prolymphocytic leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA PROLYMPHOCYTIC LEUKEMIA RICHTER'S SYNDROME SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Research Site

Boston, Massachusetts, 2215, United States
Research Site

New Hyde Park, New York, 11042, United States
Research Site

New York, New York, 10021, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Seattle, Washington, 98122, United States
Research Site

Tacoma, Washington, 98405, United States
Research Site

Milan, 20132, Italy
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

London, SE5 9RS, United Kingdom
Research Site

Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.